Chemomab Therapeutics Announces New Publications Reinforcing The Clinical Potential Of Its Ccl24-neutralizing Antibody Cm-101 In Primary Sclerosing Cholangitis

A new study has confirmed the potential of Chemomab’s CCL24-neutralizing antibody, CM-101, to treat primary sclerosing cholangitis (PSC), a rare fibrotic liver disease. The study used machine learning to identify the involvement of CCL24 and its link to disease progression and severity. The results highlight the potential of CM-101 as a promising therapy for PSC.